Notice: 函数 WP_Styles::add 的调用方法不正确。 The style with the handle "storefront-woocommerce-style" was enqueued with dependencies that are not registered: storefront-style. 请查阅调试 WordPress来获取更多信息。 (这个消息是在 6.9.1 版本添加的。) in /wordpress/wp-includes/functions.php on line 6260

KB-1189

Monalizumab

Home » Monalizumab

Background of Monalizumab

CD94/NKG2A heterodimer is a type II transmembrane receptor that belongs to the C-type lectin family containing a single intracellular ITIM domain that recognizes HLA-E, a nonclassical HLA-I molecule. NKG2A participates in NK cell-mediated self-tolerance upon binding to HLA-E, which in turn has been related to tumor evasion in a wide variety of solid tumors and hematological malignancies, such as MM . Monalizumab is a humanized IgG4 antibody that abrogates NKG2A inhibitory function by impeding its interaction with HLA-E. This mAb has already shown promising results in head and neck squamous cell carcinoma (in combination with cetuximab) and gynecological cancers in phase II clinical trials.

Specifications

Catalog Number:
KB-1189
Antibody Name:
Monalizumab
Isotype:
Human-IgG4-S228P, kappa
FC Muations:
S228P
Target:
NKG2A
Species Reactivity:
Human
Host Cell Line:
EXPI CHO
Purification Method:
Affinity purified
Concentration:
>2 mg/mL
Formulation:
50 mM sodium citrate,150mM NaCl,pH5.5
Purity:
>95% by SDS-PAGE and SEC-HPLC
Validation:
ELISA
Endotoxin Level:
<0.2 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Storage:
It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

  1. Van Montfoort N, Borst L, Korrer MJ, Sluijter M, Marijt KA, Santegoets SJ, van Ham VJ, Ehsan I, Charoentong P, Andre P, et al. NKG2A blockade potentiates CD8 T cell immunity induced by Cancer vaccines. Cell. 2018;175(7):1744–55 e1715.
  2. Andre P, Denis C, Soulas C, Bourbon-Caillet C, Lopez J, Arnoux T, Blery M, Bonnafous C, Gauthier L, Morel A, et al. Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. Cell. 2018;175(7):1731–43 e1713. 
  3. Braud VM, Allan DS, O'Callaghan CA, Soderstrom K, D'Andrea A, Ogg GS, Lazetic S, Young NT, Bell JI, Phillips JH, et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature. 1998;391:795–9.